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Abstract 
The specificity of the interaction of cytochrome b5 with different forms of cytochrome P-450 was examined. Immtmopurification f cytochromes 
P-450 IA1, 2B1 and 2El from rat liver microsomes resulted in co-purification of cytochrome b5 with cytochrome P-450 forms 2BI and 2El but not 
1A1. This specificity was evaluated in conjunction with multiple sequence alignment of the three cytochrome P-450s and a molecular model of the 
cytochrome P-450-cytochrome b5 complex [(1989) Biochemistry 28, 8201-8205]. These analyses uggest two basic residues in the arginine cluster 
region of P-450, which are present in P-450s 2B1 and 2El but are absent in P-450 1A1, as potential binding sites for cytochrome bs. 
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1. Introduction 2. Materials and methods 
The cytochromes P-450 are a family of enzymes that 
catalyze the oxidation of a wide array of lipophilic com- 
pounds [1-4]. These include xenobiotics uch as drugs 
and carcinogens, as well as the endogenous prosta- 
glandins, fatty acids and steroids. Although the amino 
acids in the substrate binding site define the substrate 
specificity of the individual forms of P-450, other unde- 
fined regions on the P-450 surface are also functionally 
active as they interact with NADPH-cytochrome P-450 
reductase and cytochrome b5 [5]. The reductase is an 
essential component of the mixed function oxygenase 
system and can transfer two electrons to all forms of 
microsomal P-450 during the catalytic ycle, In contrast, 
the role of cytochrome bs, which may donate only the 
second of these electrons, is more complex, as its effect 
on P-450-catalyzed activities exhibits P-450 form-speci- 
ficity [6--15]. 
In this study we show that cytochrome b5 co-purifies 
to variable xtents with different forms of rat liver P-450, 
thus suggesting differential stabilities of the P-450--cyto- 
chrome b5 complexes. This P-450 form-specificity was 
used in conjunction with multiple sequence alignment of 
P-450s and molecular modeling to identify the amino 
acid residues of mammalian P-450s that interact with 
cytochrome bs. 
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2.1. Preparation of rat liver microsomes 
Male Sprague-Dawley rats (6 weeks old) were injected intraperitone- 
ally daily with 3-methyicholanthrene (MC) (40 mg/kg of body weight 
for 3 days) to induce P-450 1AI, or with phenobarbital (PB) (80 mg/kg 
of body weight for 3 days) to induce P-450 2B1. Rats were treated with 
25% acetone (AC) in their drinking water for 3 days to induce P-450 
2El. Liver microsomes were prepared by differential centrifugation a d 
stored in 0.25 M sucrose at -80°C. Protein concentrations were deter- 
mined by the BCA protein assay (Pierce). 
2.2. Immunopurification of P-450 
Microsomes were solubilized with 0.5% Emulgen 911 (Kao-Atlas 
Chemical Co.) and P-450s were immunopurilied using Sepharose-MAb 
immunoadsorbents as previously described [16], with the modification 
that P-450 was eluted from the immunoadsorbent wi h 40 mM sodium 
phosphate, pH 3.0. MAb 1-36-1 to P-450 1AI [17], MAb 2-66-3 to 
P-450 2B1 [18] and MAb 1-98-1 to P-450 2El [19] were used to im- 
munopurify these P-450s from MC-, PB- and AC-microsomes, respec- 
tively. These MAbs were obtained from Dr. S.S. Park (National Cancer 
Institute). Immunopurified P-450s were separated by SDS-PAGE on 
a 10-20% gradient gel (Daiichi Pure Chemicals, Tokyo, Japan), and 
visualized by Coomassie brilliant blue staining of the gel. 
2.3. Immunoblot analysis 
Immunopurified P-450s were electroblotted from the gel to polyvi- 
nylidene difluoride membranes (Immobilon, Millipore) [20], using a 
transfer solution of 50 mM Tris-glycine (pH 8.2), 20% methanol. Immu- 
nodetection was performed as described [16], using the above anti-P- 
450 MAbs, or MAb 1-17-1 to cytochrome b5 [21]. Densitometric anal- 
ysis of stained bands was performed with a Molecular Dynamics Com- 
puting Densitometer. 
2.4. Sequence alignment and molecular modeling 
Multiple alignment of protein sequences were performed with the 
MACAW program [22], implemented on an IBM PSI2 Model 80 micro- 
computer. For visualization of the crystal structures of P-450cam [23] 
and cytochrome b5 [24], their coordinates (data sets 2CPP and 3B5C, 
respectively) were obtained from the Protein Data Bank (Brookhaven 
National Laboratories, Upton, NY), and displayed on a Silicon Graph- 
ics 4D/70G workstation using QUANTA molecular modeling software 
(Polygen Corp., Waltham, MA). 
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Fig. 1. SDS-PAGE analysis of immunopurified P-450s. Lanes 1-3 con- 
tain 20 pg liver microsomes (MICS) from rats treated with MC, PB and 
AC. Lanes 4--6 contain P-450s 1A1, 2B1 and 2El which were im- 
munopurified from these microsomes using MAbs 1-36-1, 2-66-3 and 
1-98-1, respectively. Lane 7 contains molecular weight markers. Pro- 
teins were stained with Commassie brilliant blue. 
the immunopurified P-450 and cytochrome b5 bands 
were quantitated in order to gauge the relative xtent of 
cytochrome b5 co-purification with each P-450. The 
staining intensities of these proteins were first corrected 
for their different molecular masses, using values of 54.5, 
52.2 and 17.0 kDa for P-450s 2B1, 2El and cytochrome 
bs, respectively. The resultant molecular cytochrome 
bs:P-450 ratios were 0.46+0.14 for 2El and 
0.11 + 0.04 for 2B1. Based on the sensitivity limit of 
Commassie brilliant blue staining, we estimate that the 
cytochrome bs:P-450 ratio was less that 0.02 for 1A1. 
The co-purification data thus indicates that, under our 
immunopurification conditions, the stability of the cyto- 
chrome b5 complex with P-450 varies in the order 
2El >2B1 >> 1A1. 
Since cytochrome b5 did not co-purify with P-450 1A 1, 
we sought o determine whether the MAb used for im- 
munopurification of this P-450, 1-36-1, inhibited the 
P-450-cytochrome b5 interaction. The immunopurifica- 
tion was thus also carried out using MAb 1-7-1, which 
binds P-450 1A1 at a different, non-overlapping epitope 
[25]. The results were the same as with the MAb 1-36-1 
immunopurification, as cytochrome b5 was also unde- 
1 2 3 4 5 6 
3. Results and discussion 
P-450s were immunopurified from liver microsomes of 
rats treated with MC, PB or AC, using MAbs to the 
major form of P-450 induced by these agents. Fig. 1 
shows the total microsomal ( anes 1-3) and immunopuri- 
fled (lanes 4-6) proteins. The latter yielded single bands 
in the P-450 region which corresponded to P-450 forms 
1A1, 2B1 and 2El, respectively. However, an additional 
17 kDa protein was co-purified with P-450s 2B1 (lane 5) 
and 2El (lane 6) but was undetectable in the lane con- 
taining P-450 1A1 (lane 4). Since the size of this protein 
corresponded to that of cytochrome bs, immunodetec- 
tion with MAb 1-17-1 to cytochrome b5 was employed 
to verify its identity. The immunoblot (Fig. 2), as ex- 
pected, revealed cytochrome b5 in all the microsomal 
samples (lanes 1-3). The MAb also immunoreacted with 
the 17 kDa protein that co-purified with 2B1 and 2El 
(lanes 4 and 6, respectively), in accordance with the 
Commassie brilliant blue-stained gel in Fig. 1. These 
data show that cytochrome b5 co-purified with P-450s 
2B1 and 2El but not 1A1. 
The Commassie brilliant blue staining intensities of 
MICS 
Fig. 2. Immunoblot of cytochrome bs in microsomes and immunopuri- 
fled P-450 samples. Lanes 1-3 contain 20/zg liver microsomes (MICS) 
from rats treated with PB, MC and AC. Lanes 4-6 contain the P-450s 
immunopurified from these microsomes using MAbs 2-66-3, 1-36-1 and 
1-98-1, respectively. MAb 1-17-1 to cytochrome b5 was used for immu- 
nodetection. 
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Fig. 3. Multiple sequence alignment of P-450s 1A1, 2B 1 and 2El. The sequences were aligned using the MACAW program. Upper case denotes regions 
of sequence similarity. Lys and Arg amino acids are shown in reverse type. The aligned residues corresponding to those in P-450cam (R72, R112, 
K344 and R364) which interact with cytochrome b5 on the basis of a model of the P-450cam-cytochrome b~ complex [29] are indicated by arrows. 
A previously proposed [33] cytochrome b5 binding region in enclosed by a box. Basic residues in this region which are present in P-450s 2BI and 
2El but not 1A1 are denoted by asterisks. 
tectable (data not shown). This result indicates that cyto- 
chrome bs does not co-purity with P-450 1A1 because 
of low affinity rather than from MAb inhibition of the 
P-450 1A1--cytochrome b5 interaction. 
We next employed the P-450 specificity of cytochrome 
b5 co-purification along with the sequences of these 
P-450s to identify the P-450 amino acid residues involved 
in binding to cytochrome bs. Multiple sequence align- 
ment of the three P-450s was performed and yielded the 
optimal alignment displayed in Fig. 3. Previous studies 
have established the importance of electrostatic contacts 
in the P-450-cytochrome b5 interaction, involving basic 
P-450 residues [9,26-28]. The basic residues in homolo- 
gous regions are thus emphasized in Fig. 3. It is evident 
that these are conserved at numerous positions which are 
all candidates for interaction with cytochrome bs. How- 
ever, the primary sequence data alone cannot provide 
further information on which of these residues are in- 
volved in binding. 
Recent computer modeling studies employed the 
known crystal structures of the individual proteins to 
develop a model of the P-450cam--cytochrome b5 com- 
plex [29,30]. In this model, P-450cam basic residues Arg- 
72, Arg-ll2, Lys-344 and Arg-364 are suitably posi- 
tioned for electrostatic contacts with the cytochrome b5 
carboxyls of residues Glu-48, Asp-60, Glu-44 and heme 
propionate. The equivalent positions of these four 
P-450cam residues in P-450s 1A1, 2B1 and 2El are de- 
noted by the arrows in Fig. 3, and are based on extensive 
sequence alignments of a large number of P-450s [31]. In 
all three P-450s, P-450cam Arg-72 is replaced by Lys, 
P-450cam Arg-ll2 and Arg-364 are conserved, and 
P-450cam Lys-344 is replaced by Leu. Acidic-basic resi- 
due pairing is thus conserved in three out of the four 
positions, and the fourth position is also identical in the 
three P-450s. The Lys-344--+Leu substitution may be tol- 
erable and not alter the P-450-cytochrome b5 interaction 
since this residue does not have a regular secondary 
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structure in P-450cam and should thus be more mobile, 
while the three basic residues are found in helical regions. 
The three P-450s should thus similarly interact with cyto- 
chrome b5 if these previously identified P-450 residues 
play a predominant role in binding. Our finding that the 
binding strength is P-450 form-specific thus indicates a
role for an additional P-450 residue(s). Examination of 
the proposed P-450cam-cytochrome b5 contact region 
via molecular modeling revealed that, like Arg-112, Arg- 
109 is also exposed on the exterior surface and is suitably 
positioned to interact with Asp-60 of cytochrome bs, 
P-450cam Arg-109 is conservatively substituted with Lys 
in P-450s 2B1 and 2El, but with hydrophobic Ala in 
P-450 1A1, as denoted by the asterisk in Fig. 3. Based 
on our result hat cytochrome b5binds to P-450s 2B 1 and 
2El but not P-450 1A1, the residue corresponding to
P-450cam Arg-109 may also interact with Asp-60 of cy- 
tochrome bs. However, the P-450cam Arg-112 equivalent 
residue retains a critical role, based on a mutagenesis 
study which showed that it is essential for binding of 
mouse P-450 2A5 to cytochrome b5[32], and the observa- 
tion that it is 100% conserved [31]. 
Although the electrostatic interaction model [29] thus 
suggests P-450cam Arg-109 as a potential interaction 
site, our data may also be interpreted in terms of a com- 
parative sequence analysis which has identified the re- 
gion corresponding to P-450cam residues 108-124 as a 
putative cytochrome b5binding site [33]. Examination of 
the basic residues in this region, which is indicated by the 
box in Fig. 3, reveals an additional position (asterisk) 
with Lys in P-450s 2B1 and 2El and Ser in P-450 1A1. 
These analysis thus yield two sites in P-450s 2B1 and 2El 
that potentially interact with cytochrome bs. Although 
these were derived on the basis of charge-pairing, addi- 
tional residues probably also stabilize the P-450-cyto- 
chrome b5 complex by hydrophobic and hydrogen bond- 
ing interactions. 
A basic question in P-450 structure-function concerns 
the binding of various functional modulators to P-450. 
Lipids and NADPH-cytochrome P-450 reductase are es- 
sential cofactors for all P-450s, and their interactions 
with P-450s have been extensively studied. While it is 
non-essential, cytochrome b5 regulates P-450 activity in 
a more complex manner since it may both transfer the 
second electron required for P-450-mediated substrate 
oxidations and change P-450 conformation [9,27,34]. 
The complexity of its action is illustrated by the differen- 
tial effect of cytochrome b5 on the activity of a single 
P-450 towards different substrates [14,35-37], and that 
it can enhance or inhibit P-450 activities in artificially 
reconstituted systems [7,8,12,13,38-41 ]. Thus one cannot 
simply infer the relative affinities of cytochrome b5 for 
different forms of P-450 from its effect on P-450 cata- 
lyzed activities. 
The interactions of P-450s with cytochrome b5 have 
accordingly been examined from various perspectives. 
Previous work established that cytochrome b5(i) changes 
the spin state of rat P-450s 2Cll [9] and 2B1 [34] and 
rabbit P-450 2B4 [9,27]; (ii) changes the magnetic circular 
dichroism of rabbit 2B4 [43]; (iii) complexes with rabbit 
P-450 2B4 via chemical crosslinking [26]; (iv) binds rat 
P-450 2C7 [43] and mouse 2A5 [32,41] by affinity chrom- 
atography; (v) inhibits phosphorylation f rabbit P-450 
2B4 by cAMP-dependent protein kinase [44,45]; and (vi) 
inhibits phosphorylation a d stabilizes P-450 2B1 from 
denaturation [45]. Since various laboratories have em- 
ployed a variety of criteria nd different P-450s to evalu- 
ate the P-450~ytochrome b5 interaction it is difficult o 
assess the relative strengths of this interaction for differ- 
ent P-450s. However, our conclusions concerning P-450 
form-specificity are based on the application of a single 
criterion to three P-450s. We point out, however, that 
although cytochrome bs did not co-purify with P-450 
1A1 during our immunopurification procedure, cyto- 
chrome b5 has been found to stimulate P-450 1Al-cata- 
lyzed oxidation of diethylstilbestrol under the different 
experimental conditions found in a reconstituted system 
[46]. However, since only P-450 1A1 was evaluated for 
activation by cytochrome b5 one cannot make conclu- 
sions regarding P-450 specificity from this study. 
The P-450 specificity of cytochrome b5 action may 
derive from variations in (i) affinity of P-450 for cyto- 
chrome bs, (ii) cytochrome bs-induced changes in P-450 
conformation, which alters binding to substrate or inter- 
action with NADPH-cytochrome P-450 reductase, or 
(iii) the rate of electron transfer from cytochrome b5 to 
P-450. In this study we examined the first of these factors 
and found that, under the conditions of co-purification, 
a P-450 in the 1A subfamily interacts more weakly than 
P-450s in the 2B and 2E subfamilies. Although sequence 
alignment of these P-450s suggested several amino acids 
which potentially interact with cytochrome bs, further 
localization of the interacting residues requires addi- 
tional studies which employ a single criterion to measure 
cytochrome b5binding to a variety of P-450s from differ- 
ent families. 
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